<SEC-DOCUMENT>0001628280-18-013796.txt : 20181106
<SEC-HEADER>0001628280-18-013796.hdr.sgml : 20181106
<ACCEPTANCE-DATETIME>20181106165753
ACCESSION NUMBER:		0001628280-18-013796
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20181106
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181106
DATE AS OF CHANGE:		20181106

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		181163744

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a8kvibativacquisitionannou.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sd8dcb74b18584d9db4384d3483c64d39"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;-sec-extract:summary;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;">FORM 8-K</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PURSUANT TO SECTION&#160;13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.5546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:52%;"></td><td style="width:48%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of report (date of earliest event reported):                &#160;                      November 6, 2018 (November 1, 2018)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:20pt;"><font style="font-family:inherit;font-size:20pt;">CUMBERLAND PHARMACEUTICALS INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">__________________________________________</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:0%;"></td><td style="width:39%;"></td><td style="width:28%;"></td><td style="width:33%;"></td></tr><tr><td><font>&#160;</font></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Tennessee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">001-33637</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">62-1765329</font></div></td></tr><tr><td><font>&#160;</font></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or other jurisdiction of incorporation)</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission File Number)</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(IRS Employer Identification No.)</font></div></td></tr><tr><td><font>&#160;</font></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2525 West End Avenue, Suite 950, Nashville, Tennessee 37203</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of principal executive offices) (Zip Code)</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">(615) 255-0068&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Registrant's telephone number, including area code:  </font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">____________________________________________</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Former name or former address, if changed since last report)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o </font><font style="font-family:inherit;font-size:10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o </font><font style="font-family:inherit;font-size:10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o </font><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:120%;padding-bottom:20px;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o </font><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#160;240.12b-2 of this chapter).</font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emerging growth company </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1.01 Entry into a Material Definitive Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 6, 2018, Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221; or &#8220;Cumberland&#8221;) announced a definitive agreement to acquire VIBATIV</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;from Theravance Biopharma. Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the delivery of high-quality prescription brands to improve patient care.  Theravance Biopharma is a diversified pharmaceutical organization with the core purpose of helping improve the lives of patients suffering from serious illness. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">VIBATIV</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(telavancin) is a patented, FDA approved anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the agreement with Theravance Biopharma, Cumberland will assume full responsibility for the product including its marketing, distribution, manufacturing and regulatory activities. Cumberland will support VIBATIV in the United States through its established hospital sales organization. The Company expects to selectively expand its sales force, medical science liaison and corporate teams to ensure the needed support of VIBATIV as well as its oncology and acute care brands.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The financial terms include a $20 million payment to Theravance Biopharma upon closing, a $5 million additional payment in early 2019, and tiered royalties up to 20% on future U.S. net product sales. The agreement is expected to close in mid-November 2018, pending customary closing conditions.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 7.01 Regulation FD Disclosure</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 6, 2018, Cumberland Pharmaceuticals Inc. Cumberland issued a press release announcing the agreement.  A copy of the press release is attached as Exhibit 99.1 and is incorporated by reference in this Item 7.01.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This information is being furnished under Item 7.01 of this Current Report on Form 8-K and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Statements and Exhibits</font></div><div style="line-height:174%;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)  Exhibits</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.5625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:20%;"></td><td style="width:13%;"></td><td style="width:67%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Exhibit No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="vibativannouncementpressre.htm"><font style="font-family:inherit;font-size:10pt;">Press release dated November 6, 2018</font></a></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.3359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:7%;"></td><td style="width:61%;"></td><td style="width:32%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cumberland Pharmaceuticals Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated: November 6, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">By: /s/ Michael Bonner</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name: Michael Bonner</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title: Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>vibativannouncementpressre.htm
<DESCRIPTION>PRESS RELEASE VIBATIV
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s0712f0533e95435f9a7ff981fe59ae12"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;"><img src="cumberlanda11.gif" alt="cumberlanda11.gif" style="height:85px;width:374px;"></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CUMBERLAND PHARMACEUTICALS </font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">TO ACQUIRE VIBATIV</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174; </sup>&#160;</font></div><div style="line-height:174%;padding-bottom:24px;padding-top:32px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">FDA approved injectable anti-infective with life-saving potential</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Nashville, Tennessee, (November 6, 2018)</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">- Cumberland Pharmaceuticals Inc. </font><font style="font-family:inherit;font-size:12pt;">(NASDAQ:CPIX) announced today that it has entered into a definitive agreement to acquire VIBATIV</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;from Theravance Biopharma. Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the delivery of high-quality prescription brands to improve patient care. Theravance Biopharma, Inc. is a diversified pharmaceutical organization with the core purpose of helping improve the lives of patients suffering from serious illness. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">VIBATIV</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(telavancin) is a patented, FDA approved anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin &amp; skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Under the terms of the agreement, Cumberland will assume full responsibility for the product including its marketing, distribution, manufacturing and regulatory activities. Cumberland will support VIBATIV in the United States through its established hospital sales organization. The Company expects to selectively expand its sales force, medical science liaison and corporate teams to ensure the needed support of VIBATIV as well as its oncology and acute care brands.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The financial terms include a $20 million payment to Theravance Biopharma upon closing, a $5 million additional payment in early 2019, and tiered royalties of up to 20% on future US net product sales. Cumberland expects that the addition of VIBATIV will be accretive to the Company&#8217;s earnings. </font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;VIBATIV is a lifesaving product for certain difficult to treat infections, and we are honored to be selected to acquire and transition the brand to our existing hospital acute care infrastructure,&#8221; said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. &#8220;Our immediate plan for VIBATIV is to ensure a smooth transition of the product supply and medical support to current users of the brand. We will then launch our hospital promotion and medical initiatives to help ensure that the product is available to the patients who need it. We are very optimistic about the opportunity that VIBATIV will offer Cumberland.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">&#8220;Following an extensive process involving discussions with several interested parties, we determined that Cumberland was best positioned to optimize the value of the VIBATIV brand and ensure the product&#8217;s important therapeutic benefits reach as many patients as possible,&#8221; said Rick E Winningham, chairman and chief executive officer of Theravance Biopharma.  &#8220;We believe that Cumberland&#8217;s track record of successfully </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">marketing and selling hospital-based products, combined with VIBATIV&#8217;s existing base of hospital formulary inclusions, positions the company to drive commercial success for VIBATIV as a flagship product.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The transaction is expected to close in mid-November, pending satisfaction of customary closing conditions.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cumberland will provide additional remarks on its upcoming third quarter 2018 earnings call.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About VIBATIV</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup>&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">VIBATIV</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(telavancin, injection) was discovered in a research program dedicated to finding new antibiotics for serious infections due to </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">Staphylococcus aureus (S. aureus)</font><font style="font-family:inherit;font-size:12pt;">&#32;and other Gram-positive bacteria, including MRSA and MSSA. VIBATIV is a once-daily, injectable lipoglycopeptide antibiotic with </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">in vitro</font><font style="font-family:inherit;font-size:12pt;">&#32;potency, bactericidal activity within six hours, and penetration into target infection sites. The drug is approved in the U.S. for the treatment of adult patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">S. aureus</font><font style="font-family:inherit;font-size:12pt;">&#32;when alternative treatments are not suitable. In addition, VIBATIV is approved in the U.S. for the treatment of adult patients with complicated skin &amp; skin structure infections (cSSSI) caused by susceptible isolates of Gram-positive bacteria, including </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">S. aureus</font><font style="font-family:inherit;font-size:12pt;">, both methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) strains. The product labeling also describes the use of VIBATIV in treating patients whose pneumonia or skin infection is complicated by concurrent bacteremia. The product's proven efficacy against difficult-to-treat Gram-positive infections has been demonstrated in several large, multinational registrational studies, which involved one of the largest cohorts of patients with </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">S. aureus</font><font style="font-family:inherit;font-size:12pt;">&#32;infections studied to date. Importantly, these studies demonstrated significantly higher cure rates for VIBATIV as compared to vancomycin in HABP/VABP due to any single Gram-positive pathogen or </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">S. aureus</font><font style="font-family:inherit;font-size:12pt;">&#32;with vancomycin MIC &#8805;1 &#181;g/mL. Additionally, there is extensive and well-documented evidence of the drug's </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">in vitro</font><font style="font-family:inherit;font-size:12pt;">&#32;potency and </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">in vivo</font><font style="font-family:inherit;font-size:12pt;">&#32;activity against a broad collection of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant. For full prescribing information, visit </font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">www.vibativ.com</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About Cumberland Pharmaceuticals Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:24px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the delivery of high-quality prescription brands to improve patient care. The Company develops, acquires, and commercializes brands for the hospital acute care, gastroenterology, and oncology market segments. </font></div><div style="line-height:120%;padding-bottom:24px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">For more information, please visit </font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">www.cumberlandpharma.com</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About Theravance Biopharma, Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Theravance Biopharma, Inc. is a diversified biopharmaceutical company with the core purpose of creating medicines that help improve the lives of patients suffering from serious illness. The company&#8217;s research efforts are focused in the areas of inflammation and immunology, with the goal of designing localized medicines that target diseased tissues, without systemic exposure, in order to maximize patient benefit and minimize risk. These efforts leverage years of experience in developing localized medicines for the lungs to treat respiratory disease. The first potential medicine to emerge from this research focus on immunology and localized treatments is an oral, gut-selective pan-Janus kinase (JAK) inhibitor, currently in development to treat a range of inflammatory intestinal diseases. The company&#8217;s pipeline of internally discovered product candidates will continue to evolve with the goal of creating transformational medicines to address the significant needs of patients.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:24px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">For more information, please visit </font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">www.theravance.com</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Forward-Looking Statements</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This release contains forward-looking statements within the meaning of the federal securities laws, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. These forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from them. Some important factors which may cause results to differ from expectations include: market conditions; competition; an inability of manufacturers to produce Cumberland's products on a timely basis or failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers; maintaining an effective sales and marketing infrastructure; availability of additional debt and equity capital required to finance the business model; market conditions at the time additional capital is required; our ability to continue to acquire branded products; product sales; management of our growth and integration of our acquisitions; our ability to close the transaction, as well as other risks discussed in the &#8220;Risk Factors&#8221; section of the Company's most recent Annual Report on Form 10-K, and other filings with the SEC. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"># # #</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Investor Contact:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Media Contact:</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Erin Smith</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Jeff Bradford</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Corporate Relations</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">the Bradford Group</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(615) 255-0068</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">(615) 515-4880</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>cumberlanda11.gif
<TEXT>
begin 644 cumberlanda11.gif
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M.N0GG3[<XBNI?IO?*;G>*7.FMVZ[2K)#"3OK:/%-%8/E)GF=9YY5![(//C0
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M)R.J$RZ:!BN_@A.7I=PUV7G!5[(O(ZY(JV7*/+*E.&)<Z'2B0U-6/LD'UG6
M B@80>7Y,02 ",$#<)FYYYF8&H9$\11Z(0[D.="+J=Q7=;0R(L6YQ+_2M-@H
M25)CB-DX7SV^W7(W2.$$IV3!-)VQD'R\LY*LE6!4A:J1)AG'_M$W?Q;6SBY-
M3,&L$E&0+-TJ!![@1T#T8VL^T <'ULR!'[3Y_P<'\ $9&-1!JISNRM<#A)X9
M$<0^\[G/ NP8B$/@7SD.VI6J K%5K.4D^DX(Q'P&#:#Y3&D_6_HD(8;TGBU=
M:3Z#6%5ZMO2D+VTN.U^% "'V"GT9AT/# F#043Z@6N3!"$*?#R2']B*Y0OUG
M3O<YFJ5&X1T?[!$', #%UVW>%%"!V7=N !#028D/?J" 'UC;VFO6AYI_( X(
MY"S:N%4AA:F! ""8^]SH3C<5($#"*9S"W*4I+0DA@(!WG_5)[C8WNUE""@.8
M^P$DH8*_TTWP<QL  0<08 '>7?"& \$/!Q#) 1CN<(,C@ H UQ<CQ@"$4U!!
ME2^9>,>YLYK0/  (_MQN &PB]#LJV-LD#!AXQ2].C2F8) 0]X-P!0D"2+/M
M ]"KH (.,(4Y/[E3J6ASM:O]9C=S8!I0U\<!R! MEP2!'P8X1=;W88!]<-WK
M!A  UT\A]GW3!0("$$ ">J#3#9!= %/J']K3SH/(A*0  @B[ #8@K#&D_>M>
M!WS7 Y_U1@5;*P7 >M?#/OC&@WT?9!\55_ ^=LCO(^^6)_SE3\%WM?0C5 (
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M *<P!H!P@W"7+X82@R@G@>*',"'A=_Q7$L7(%6C3D0^0BA+H!=/A!=+H %0
M!!L@#S"Y0R+Q "-##=FX$HC&3%<(9VYV;>C89J3@?>U("M?V ZE -"#D$:&8
M #18$O(0*@G  PO&A*X'DB6Q 7I'>PPR=U20B!<80#R0=QK0@ !W*LSXBE59
M$@[@>I6(%?48<<T!')0G?R$1E-JQ?TD( "9)D=%E7^I"@@$)D )0B?_"%7;)
M=8E9>+ZX-6/0=7$7;5Q!E*=PF"5!B ; #[37#\='#1MP  6 E.1!*&CA  A@
M#S4B%Y9"4.)PCLK9_Y73\'0_ '7>]V8'\ -30%,R-649Z'HT^(L>P3G/-Q(
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MRZ&WXV[SEVKWGZV7[.2;TWT]>R;QRST/=JXG]*'' )\HB&6=*IM1'2R%"E,
M =2B:VKA7_E9AO(&WM %$EBN%QC2 Y\#!+ZD"PCP^(Y?;KXD?%Q/W%3@2XS/
M^)#_^)D_!L*7V#JM+1I@W;$Q!4#  PB D2%!;H_?^K[T^)B/^9#*GXUJ;K'O
M^IH_^0APNA@HB:=;&H]S'4M9;@B0_Y.2,SV1K_F=KRV;+]A0K"V3?K2M<:SF
M9JE^6FY 8/Q0@C:2" 08^+JVS_FWO_N0FL8M<1I+3B^BG H'H/?*3>I_;QS
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M^#J0P\8Z LI#K?1Z#\.?M&H.1-,HFH^\@7P0![>Y])/@!_XXF";)$:;11Q\
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M'QO'  0!*/%H&.,E/<S'QU^^#B$%2$ "#C C+T23"FD+S10$D !J.$N634S
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EENT,R5'!1LVO-'5DG#8]));2UFF4$%Y62XV/G4S60/F'@   .P$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
